<p>Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities</p>
Ruidi Jiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Hong Ge(Zhengzhou University), Hui Luo(Sun Yat-sen University), Wenbo Xu(Fifth Affiliated Hospital of Zhengzhou University)
Cited by 39
Related Papers
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
|Nature Medicine|2024|162
A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
|BMC Cancer|2015|160
Self-improving generative foundation model for synthetic medical image generation and clinical applications
|Nature Medicine|2024|115
Long non-coding RNA HOTAIR knockdown enhances radiosensitivity through regulating microRNA-93/ATG12 axis in colorectal cancer
|Cell Death and Disease|2020|109
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
|Cancer Communications|2020|54